Peptides DB
Research-centric peptide and protocol reference hub
Study 65 of 65HCG (Human Chorionic Gonadotropin) literatureSeminars in oncology · Case report2026

Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma.

This case report suggests that early salvage therapy with pembrolizumab may be a viable option for patients with chemo-refractory gestational choriocarcinoma, but further research is needed to confirm these findings.

Read at Seminars in oncologyAdd to compare

Where it sits

this study against the rest of the hcg (human chorionic gonadotropin) corpus
9
Preclinical
51
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

This case report discusses a 45-year-old female with ultra-high-risk gestational choriocarcinoma who received early salvage immunotherapy with pembrolizumab after resistance to first-line EMA-CO chemotherapy. The treatment resulted in rapid normalization of β-hCG levels and sustained complete remission. No immune-related adverse events were observed during treatment.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=12026

Abstract

The authors’ words, as Seminars in oncology supplied them

Gestational Choriocarcinoma (GC) may present as a highly aggressive neoplasm. While typically chemo-sensitive, management of multi-drug-resistant disease remains a clinical challenge, requiring potentially toxic salvage regimens. We report the case of a 45-year-old female with history of B-cell Acute Lymphocytic Leukemia, who presented with intracranial hemorrhage due to metastatic choriocarcinoma. The disease was classified as ultra-high risk (FIGO stage IV, WHO score 13). Following resistance to first-line EMA-CO chemotherapy, the patient received early salvage immunotherapy with pembrolizumab, instead of second-line cytotoxic regimens. This approach resulted in rapid normalization of β-hCG levels and sustained complete remission. Treatment remains ongoing and well tolerated without any immune-related adverse events observed. This case highlights the efficacy of pembrolizumab in chemo-refractory disease and suggests a potential benefit for certain high-risk patient groups as an early salvage option that could minimize toxicity while achieving favorable survival outcomes.

Background

Gestational choriocarcinoma (GC) is known for its aggressive nature and typical sensitivity to chemotherapy. However, the management of multi-drug-resistant cases poses significant challenges, necessitating alternative treatment strategies. This study presents a case where early salvage therapy with pembrolizumab was utilized in a patient with ultra-high-risk GC, aiming to explore its potential as a less toxic alternative to traditional cytotoxic regimens.

Methods

This is a case report detailing the treatment of a 45-year-old female with a history of B-cell Acute Lymphocytic Leukemia and FIGO stage IV choriocarcinoma. Following resistance to first-line EMA-CO chemotherapy, the patient received pembrolizumab as an early salvage therapy. The duration and specific dosing regimen of pembrolizumab are not reported in the abstract.

Results

The treatment with pembrolizumab led to rapid normalization of β-hCG levels. Sustained complete remission was reported, and the patient tolerated the treatment well without any immune-related adverse events.

Interpretation

While the normalization of β-hCG levels and sustained remission are promising, this case lacks a control group for comparison. The findings suggest that pembrolizumab may be beneficial for certain high-risk patients, but the clinical significance of these results remains uncertain due to the absence of larger studies. The limitations of a single case report and lack of detailed dosing information further restrict the conclusions that can be drawn.

Key findings

  • Normalization of β-hCG levels following pembrolizumab treatment.
  • Sustained complete remission observed.
  • No immune-related adverse events reported.

Limitations

  • Single case report limits generalizability.
  • No control group or comparative data provided.
  • Not reported in abstract for specific dosing or duration.

Elsewhere in the HCG (Human Chorionic Gonadotropin) corpus

BEndometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2024 · n=177 · Treatment success occurred in 94 of 177 women (53.1%).HumanBSuccessful fertility-preserving management of a viable cesarean scar ectopic pregnancy: a case report.Case reports in women's health · 2026 · n=1 · Estimated blood loss of 20 mL.HumanBEndometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · 53.1% treatment success in 177 women.HumanCSR-18292 Alters Oocyte Competence and Ovarian Transcriptomic Dynamics in Female Micebiorxiv-preprint · 2026 · Not reported in abstract.AnimalBHigh-grade endometrioid carcinoma arising from uterine serosal endometriosis with focal choriocarcinomatous differentiation and embryonal carcinoma-like morphology: a case report and literature reviewbiorxiv-preprint · 2023 · n=1 · Serum β-hCG remained persistently below 1 mIU/mL throughout follow-up.HumanBEfficacy of hysteroscopic curettage and niche resection in type II and III cesarean scar pregnancies.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2026 · n=105 · 20 (15,25) min vs 25 (20,31) min operation time, p=0.001Human